A diagnostic platform featuring high sensitivity and wide detection menu that comprehensively covers critical care, cardiovascular and cerebrovascular diseases, and other key clinical areas. The platform is widely applied in clinical departments such as laboratory medicine, emergency medicine, and I...
Manufactured by
China
Xenta Biomedical Science Co., Ltd, founded in December 2021 and headquartered in Guangzhou Development District, is a national high-tech enterprise focused on the R&D, registration, and commercialization of in vitro diagnostic (IVD) reagents and devices. With fully paid-up capital of RMB 10 million, the company is led by a team of returnee PhDs with strong international research and industry experience. It is dedicated to developing innovative POCT technology platforms under the philosophy of "Faster, Better, and More Accessible". The company drives innovation through R&D centers in Guangzhou, Xiamen, and overseas. Using its proprietary dry light-excited chemiluminescence POCT platform, it has developed leading product series and managed major national research projects. The company has published over 20 SCI papers, holds 70 patents, has obtained more than 60 EU CE certifications, and 12 FDA approvals in the United States. Currently, several product lines are actively striving for NMPA certification. Its pipeline covers key areas including cardiovascular, inflammation, oncology, hormone, and infectious diseases, demonstrating end-to-end capabilities from R&D to global commercialization. The core team comprises graduates from top universities such as Texas A&M University, Xiamen University, Sanford-Burnham Medical Research Institute, and Sun Yat-sen University, possessing multidisciplinary expertise in biomedicine, engineering, and law. The co-founders have extensive experience from leading IVD companies, having previously guided teams to achieve annual revenues exceeding several hundred million yuan and secure over 200 product certifications worldwide. Since its establishment, Xenta Biomedical Science Co., Ltd has raised tens of millions in funding and obtained ISO 13485 certification, supporting its global expansion.
✦ Product-Specific Coverage
Based on AI-matched alternatives related to this product across Suplivia's medical sourcing network.
Generated for this product
AI-matched supplier coverage based on related product alternatives.
Guangzhou Wondfo Biotech Co., Ltd.
China · 1 relevant product
Shenzhen YHLO Biotech Co., Ltd.
China · 3 relevant products
Jiangsu Sunlant Bioengineering Co., Ltd.
China · 2 relevant products
Response Biomedical
Canada · 1 relevant product
Biomerica, Inc.
United States · 1 relevant product
Anhui Huibang Biological Engineering Co., Ltd.
China · 1 relevant product
ReLIA Bioengineering(Jiangsu), Inc
China · 1 relevant product
Sekbio Co., Ltd
China · 1 relevant product
Assure Tech. (Hangzhou) Co., Ltd.
China · 1 relevant product
Jiangsu Zecen Biotechnology Co., Ltd
China · 2 relevant products
18 more relevant manufacturers available
Get free access to all relevant manufacturers for this product.
See all manufacturers →See the full supplier coverage for this product
Get free access to all relevant manufacturers, sourcing countries, and product alternatives.
✓ Free for medical industry professionals.
from other manufacturers
from other manufacturers
12 of 34 closest product alternatives
Guangzhou Wondfo Biotech Co., Ltd. · China
Chemiluminescence diagnostic platform for quantitative and qualitative analysis of biomarkers in patient samples. Delivers sensitive detection capabilities for clinical laboratory and point-of-care applications.
Shenzhen YHLO Biotech Co., Ltd. · China
A comprehensive technology platform utilizing chemiluminescence immunoassay methodology for in vitro diagnostic testing. The platform enables sensitive and specific detection of various clinical markers including reproductive, autoimmune, infectious disease, and metabolic parameters.
Shenzhen YHLO Biotech Co., Ltd. · China
An integrated biochemistry testing platform for clinical laboratory diagnostics. The system encompasses multiple biochemical assays approved for clinical use in patient sample analysis.
Jiangsu Sunlant Bioengineering Co., Ltd. · China
A microarray-based chemiluminescence immunoassay platform using hard-substrate glass slides as carriers with covalently bound monoclonal antibodies. The platform features integrated positive and negative quality control points, multi-parameter detection with up to 56 array points, and a sandwich immunoassay methodology. It combines high-sensitivity chemiluminescence detection with high-throughput biochip technology using an integrated photoelectric sensor to read all signal points simultaneously.
Response Biomedical · Canada
Integrated point of care testing platform designed for rapid diagnostic analysis in clinical environments, supporting multiple biomarker assays for immediate patient assessment and decision-making.
Biomerica, Inc. · United States
A point-of-care diagnostic platform supporting manual to high-throughput ELISA testing with easy automation capabilities. Enables laboratory-accurate results at the point-of-care.
Anhui Huibang Biological Engineering Co., Ltd. · China
Quantum dot-based detection platform for in vitro diagnostic testing of urine biomarkers. Enables multi-channel composite analysis for early detection of diabetic nephropathy and premature rupture of membranes through dry-reagent immunoassay technology. Supports both clinical laboratory quantification and point-of-care patient self-testing with mobile device image capture and server-based result analysis.
ReLIA Bioengineering(Jiangsu), Inc · China
A compact, intelligent chemiluminescence detection platform designed for accurate diagnostic testing. The system features 20+10 independent detection channels that can perform parallel testing, delivering results within 15 minutes with low maintenance costs and extended reagent shelf life. It utilizes acridinium ester chemiluminescence technology with direct marker participation in the luminescence reaction, achieving high sensitivity and stability with coefficient of variation (CV) ≤3%, combining the precision of chemiluminescence with the convenience of point-of-care testing.
Sekbio Co., Ltd · China
CLIA platform providing results in 30-60 minutes with sandwich and competitive immunoassay formats. Features very high sensitivity at pg/mL range with wide dynamic range of 3-5 logs and compatibility with major analyzers.
Assure Tech. (Hangzhou) Co., Ltd. · China
POCT Chronic Disease Monitoring Systems enable rapid point-of-care testing for chronic disease management through colloidal gold and chemiluminescence immunoassay technologies. The platform supports multiple diagnostic test series including cardiac markers, biochemical parameters, and disease monitoring. Designed for clinical laboratories and healthcare facilities requiring quick, quantitative diagnostic results.
Jiangsu Zecen Biotechnology Co., Ltd · China
Point-of-care testing chemiluminescence system for rapid diagnostic testing. Designed for use in hospitals, disease control centers, and health examination centers.
Jiangsu Zecen Biotechnology Co., Ltd · China
A point-of-care testing chemiluminescence system for rapid diagnostic analysis. This product is part of the company's automated chemiluminescence solution portfolio and is designed for use in hospitals, disease control centers, and health examination centers.
22 more product alternatives available
Create a free account to compare more product alternatives and supplier options.
© 2026 Suplivia · Home · Browse Products